Tempest Therapeutics, Inc. Payments of Loan Costs
Tempest Therapeutics, Inc. (TPST) reported Payments of Loan Costs of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfLoanCosts · last filed 2023-03-22
- Tempest Therapeutics, Inc. payments of loan costs for the quarter ending 2022-09-30 was $0.00.
- Tempest Therapeutics, Inc. payments of loan costs for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. payments of loan costs for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. payments of loan costs for the quarter ending 2021-12-31 was $2.00K.
- Tempest Therapeutics, Inc. payments of loan costs for fiscal 2021 was $95.00K.
- Tempest Therapeutics, Inc. payments of loan costs for fiscal 2020 was $0.00.
| Period end | Payments of Loan Costs 3 month | Payments of Loan Costs 6 month | Payments of Loan Costs 9 month | Payments of Loan Costs 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $2.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | $2.00K derived: sum of 3 quarters · filed 2023-03-22 | $2.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $2.00K derived: sum of 2 quarters · filed 2023-03-22 | $2.00K derived: sum of 3 quarters · filed 2023-03-22 | $36.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2021-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.00K derived: sum of 2 quarters · filed 2023-03-22 | $36.00K derived: sum of 3 quarters · filed 2023-03-22 | $95.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $34.00K derived: sum of 2 quarters · filed 2022-11-08 | $93.00K 10-Q · filed 2022-11-08 | $93.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $93.00K 10-Q · filed 2022-08-15 | $93.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $59.00K 10-Q · filed 2022-05-13 | $59.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |